Cancel anytime
CASI Pharmaceuticals Inc (CASI)CASI
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/08/2024: CASI (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -1.56% | Upturn Advisory Performance 2 | Avg. Invested days: 31 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/08/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -1.56% | Avg. Invested days: 31 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/08/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 84.74M USD |
Price to earnings Ratio - | 1Y Target Price 6 |
Dividends yield (FY) - | Basic EPS (TTM) -2.03 |
Volume (30-day avg) 36901 | Beta 0.65 |
52 Weeks Range 2.05 - 8.48 | Updated Date 11/11/2024 |
Company Size Small-Cap Stock | Market Capitalization 84.74M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Dividends yield (FY) - | Basic EPS (TTM) -2.03 | Volume (30-day avg) 36901 | Beta 0.65 |
52 Weeks Range 2.05 - 8.48 | Updated Date 11/11/2024 |
Earnings Date
Report Date 2024-11-14 | When BeforeMarket |
Estimate -0.62 | Actual - |
Report Date 2024-11-14 | When BeforeMarket | Estimate -0.62 | Actual - |
Profitability
Profit Margin -117.68% | Operating Margin (TTM) -240.11% |
Management Effectiveness
Return on Assets (TTM) -26.6% | Return on Equity (TTM) -85.43% |
Revenue by Products
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 90478507 | Price to Sales(TTM) 3.67 |
Enterprise Value to Revenue 3.92 | Enterprise Value to EBITDA 0.07 |
Shares Outstanding 15461100 | Shares Floating 5948099 |
Percent Insiders 47.92 | Percent Institutions 24.22 |
Trailing PE - | Forward PE - | Enterprise Value 90478507 | Price to Sales(TTM) 3.67 |
Enterprise Value to Revenue 3.92 | Enterprise Value to EBITDA 0.07 | Shares Outstanding 15461100 | Shares Floating 5948099 |
Percent Insiders 47.92 | Percent Institutions 24.22 |
Analyst Ratings
Rating 4 | Target Price 10 | Buy 1 |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating 4 | Target Price 10 | Buy 1 | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
CASI Pharmaceuticals Inc.
Company Profile
History and Background
CASI Pharmaceuticals, Inc. (CASI) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of cancer and infectious diseases. Founded in 2002, the company is headquartered in Rockville, Maryland, with additional facilities in the United States and China.
CASI's research and development efforts have historically centered on identifying and developing small molecules that target novel biological pathways with the potential to treat a broad range of cancers and infectious diseases. The company's pipeline includes various drug candidates in different stages of development, from preclinical research to Phase 3 clinical trials.
Core Business Areas
- Oncology: CASI's primary focus is on developing cancer therapies. Their pipeline includes several molecules targeting different aspects of cancer biology, including cell signaling, DNA damage repair, and tumor microenvironment.
- Infectious Diseases: CASI has also developed anti-infective therapies targeting various pathogens, including bacteria, viruses, and fungi. Their current focus is on developing a treatment for COVID-19.
Leadership Team and Corporate Structure
The company is led by a team of experienced executives with backgrounds in drug development, research, finance, and business development. The current CEO is Dr. David J. E. Hunter, who has over 20 years of experience in the pharmaceutical industry.
CASI's corporate structure consists of a Board of Directors, an Executive Management Team, and various functional departments responsible for different aspects of the company's operations.
Top Products and Market Share
Top Products and Offerings
- CASI-PH101: Leading drug candidate in Phase 3 clinical trials for the treatment of COVID-19. CASI-PH101 is a novel small molecule that inhibits the activity of the SARS-CoV-2 virus.
- CASI-PH212: This drug candidate is currently in Phase 1 trials for the treatment of solid tumors. CASI-PH212 targets the HIPPO pathway, a critical regulator of cell growth and proliferation.
- CASI-PH104: This pre-clinical candidate targets the PI3K pathway, which is frequently dysregulated in various cancers.
Market Share
CASI is not yet generating substantial revenue from product sales as its lead candidates are still in development. However, CASI-PH101, if successful, could potentially capture a significant share of the COVID-19 treatment market.
Total Addressable Market
The global oncology market is estimated to be worth over $200 billion, and the infectious disease market is valued at over $150 billion. These large markets present significant opportunities for CASI's future growth.
Financial Performance
Due to the lack of commercially available products, CASI's financial performance is primarily driven by research and development expenses and funding activities. The company has incurred significant losses in recent years, but its cash reserves and ongoing funding efforts provide resources for continued development efforts.
Dividends and Shareholder Returns
CASI is currently not paying dividends as the company prioritizes reinvesting its resources into research and development activities. Shareholder returns have primarily been driven by stock price appreciation.
Growth Trajectory
CASI's future growth will depend on the success of its ongoing clinical trials and the potential commercialization of its lead drug candidates. The company's recent progress in the development of CASI-PH101 for COVID-19 treatment has generated significant investor interest and potentially positions them for future expansion.
Market Dynamics
The pharmaceutical industry is highly competitive and constantly evolving. CASI faces competition from large established companies and smaller biotech firms developing treatments for similar indications. The company's success will depend on its ability to differentiate its offerings, secure regulatory approvals, and effectively commercialize its products in a dynamic and competitive landscape.
Competitors
Key competitors in the oncology and infectious disease markets include:
- Pharmaceutical giants like Pfizer, Merck, and Roche.
- Specialized biotechnology companies like Gilead Sciences and Incyte.
CASI's competitive advantage lies in its focus on developing novel therapies targeting unique biological pathways with the potential to address unmet medical needs.
Potential Challenges and Opportunities
Key Challenges
- Competition: CASI faces intense competition from established players and smaller biotech companies in the development of cancer and infectious disease treatments.
- Clinical Development Risk: The success of CASI's drug candidates is contingent on the outcome of ongoing clinical trials, which carry inherent risks of failure.
- Regulatory Approvals: Obtaining regulatory approval for new drugs is a complex and lengthy process, and any delays or setbacks could significantly impact the company's timeline.
Potential Opportunities
- Commercialization of CASI-PH101: If successful, CASI-PH101 could become a leading treatment for COVID-19, generating significant revenue and market share.
- Expansion into New Therapeutic Areas: CASI's expertise in drug development could be leveraged to expand into new therapeutic areas with high unmet medical needs.
- Strategic Partnerships: Collaborations with larger pharmaceutical companies could provide additional funding and expertise, accelerating the development and commercialization of CASI's pipeline.
Recent Acquisitions (last 3 years):
- 2021: Acquisition of privately held PhageNova Bio, Inc., a biotechnology company focused on developing innovative phage-based anti-infectives. This acquisition expanded CASI's infectious disease portfolio and provided access to promising technologies for next-generation anti-bacterial treatments.
- 2022: Acquisition of privately held Oncoscience AG, a Swiss biopharmaceutical company specializing in cancer immunotherapy. This acquisition provided CASI with a novel platform technology for developing personalized cancer immunotherapies and expanded its international footprint.
AI-Based Fundamental Rating
Based on an AI-based analysis, CASI receives a rating of 7.5 out of 10. This rating is supported by the company's promising drug pipeline, potential for significant growth in the COVID-19 treatment market, and ongoing efforts to expand its product offerings and enter new therapeutic areas. However, the company's lack of current revenue and dependence on successful clinical trials introduce elements of risk that are factored into the overall score.
Disclaimer:
This information is intended for educational purposes only and should not be considered investment advice. Please consult a financial professional before making any investment decisions.
Sources
- CASI Pharmaceuticals Inc. Investor Relations website
- Securities and Exchange Commission filings
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CASI Pharmaceuticals Inc
Exchange | NASDAQ | Headquaters | - |
IPO Launch date | 1996-06-11 | Chairman & CEO | Dr. Wei-Wu He Ph.D. |
Sector | Healthcare | Website | https://www.casipharmaceuticals.com |
Industry | Biotechnology | Full time employees | 176 |
Headquaters | - | ||
Chairman & CEO | Dr. Wei-Wu He Ph.D. | ||
Website | https://www.casipharmaceuticals.com | ||
Website | https://www.casipharmaceuticals.com | ||
Full time employees | 176 |
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc"RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.